PPD Signs Agreement HLT

Capacity management within functional service partnerships

Tim King and Brian Ford discuss the concept of moving capacity management from sponsors to their FSP vendors.

Contract Pharma  (January 2020)

China’s evolving regulatory environment: Special report

Alistair Davidson, Guoliang Liu and Bill Wang assess how the clinical trial market has responded over the past few years and analyze the future of the China market.

Regulatory Focus  (January 2020)

PPD adds clinical research site in Florida

Wilmington-based PPD now has a 52-bed clinical research unit in Orlando, Florida, with a focus on early phase trials on neurological disorders.

Wilmington Business Journal  (December 2019)

The evolving data-driven strategic feasibility model

How democratization of data is powering a new wave of opportunities.

Pharmaceutical Outsourcing  (December 2019)

PM360 2019 innovative service: SiteCoach from PPD

A shortage of high-quality sites are available for sponsors for certain indications and parts of the world. PPD recognized this obstacle and sought out to address this need.

PM360  (December 2019)

Meeting E&L expectations

PPD’s Derek Wood discusses the critical importance of extractables and leachables (E&L) evaluations related to drug product safety, efficacy and quality.

Pharmaceutical Technology  (December 2019)

Special report on liver disease: The phantom menace

Dawie Wessels of AES comments on the cause and treatment of non-alcoholic steatohepatitis (NASH).

DDNews  (December 2019)

PPD acquires unit, expands neurology capabilities for elderly patients

PPD adds clinical research unit with ‘strong’ recruiting track record to its portfolio, enabling studies on patient populations ‘more reflective’ of the products’ end-users.

Outsourcing Pharma   (December 2019)

Group names PPD best CRO provider

PPD was named Best CRO Provider at the sixth-annual World ADC Awards, according to a news release.

Greater Wilmington Business Journal  (November 2019)

The future of decentralized trials

Anna Long says the decentralizing of trials is likely to appeal to a greater diversity of patients, especially younger generations that have grown up with technology and the flexibility and interactivity it affords.

PharmaVOICE  (November 2019)